Hemosiderin deposits in chronic graft-vs.-host disease related myopathy

Martin Schmidt-Hieber1, Ali Fuat Okuducu, Gisela Stoltenburg

  • 1Medizinische Klinik III (Hämatologie, Onkologie und Transfusionsmedizin), Charité- Campus, Benjamin Franklin, Hindenburgdamm, Berlin, Germany. martin.schmidt-hieber@charite.de

Insights

Chronic graft-vs.-host disease (cGVHD) can cause rare muscle issues. This case highlights unusual hemosiderin and lipofuscin deposits in skeletal muscle, suggesting a new cGVHD manifestation.

Area of Science:

  • Hematology
  • Immunology
  • Neurology

Background:

  • Chronic graft-vs.-host disease (cGVHD) affects 20-50% of allogeneic stem cell transplant survivors.
  • Common cGVHD manifestations include skin, liver, lung, and systemic wasting syndromes.
  • Polymyositis/myopathy are rare cGVHD complications, with few reported cases.

Observation:

  • A 56-year-old male developed progressive muscular weakness and inability to walk post-allogeneic SCT.
  • Muscle biopsy revealed perifascicular atrophy with hemosiderin and lipofuscin deposits.
  • Elevated ferritin levels were noted, but standard muscle enzymes were normal.

Findings:

  • This case presents a unique combination of hemosiderin and lipofuscin accumulation in skeletal muscle within cGVHD.
  • Such deposits have not been previously reported in the skeletal muscle of cGVHD patients.
  • Deferoxamine treatment was ineffective in improving the patient's condition.

Implications:

  • This finding expands the spectrum of rare neuromuscular manifestations of cGVHD.
  • It suggests a potential role for iron and pigment deposition in cGVHD-associated myopathy.
  • Further research is needed to understand the pathogenesis and explore potential therapeutic strategies for this rare complication.

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...